Abstract 8895: Design of Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate for the Management of Hyperkalemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction (REALIZE-K Trial)

Mikhail Kosiborod,David Z.I. Cherney,Akshay S. Desai,Mark C. Petrie,Jeffrey M. Testani,Subodh Verma,Ayman Al-Shurbaji,James M. Eudicone,Donna Zarzuela

Abstract 8895: Design of Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate for the Management of Hyperkalemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction (REALIZE-K Trial)

2021

Mikhail Kosiborod
David Z.I. Cherney
Akshay S. Desai
Mark C. Petrie
Jeffrey M. Testani
Subodh Verma
Ayman Al-Shurbaji
James M. Eudicone
Donna Zarzuela

Introduction: International guideline-recommended therapies for heart failure (HF) with reduced ejection fraction (HFrEF), including mineralocorticoid receptor antagonists (MRA), are underutilized,...

Keywords:

Potassium
Cardiology
Aldosterone
Hyperkalemia
Mineralocorticoid receptor
Heart failure
Ejection fraction
Internal medicine
Placebo
Angiotensin II
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations